医药人才网 > 苏州市生物制药/医疗器械招聘 > 百济神州（苏州）生物科技有限公司招聘 > 更多OSD QC管培生招聘

OSD QC管培生 [ 投诉职位 ]

百济神州（苏州）生物科技有限公司查看地图

薪水:8000~10000元

面试通知早知道

关注麟越网微信

接收企业发给你的面试通知

基本信息

工作地点：苏州市
要求行业：生物工程、制药、环保
年龄要求：18~45岁
要求学历：本科
招聘人数：1人
工作经验：应届生
专业要求：不限

任职要求/岗位职责

根据相关的SOP或标准测试方法执行日常必须的测试

Perform the necessary tests according to the relevant SOP/Test Methods.

根据相关的SOP执行原辅料和包材的取样

Perform sampling of raw material and packaging material according to relevant SOP.

执行常规的公用系统的检测

Perform routine test of utility system.

起草检验操作规程以及实验室有关的SOP

Prepare test methods and SOPs related to QC laboratory.

必要时参与偏差调查活动并提供相关技术支持

Carry out the deviation investigation and provide the technical support as required.

承担个人安全职责，保护自己，并避免伤害他人和环境。参加该岗位的必须的安全培训并配合应急预案的演练。

Take personal safety responsibility, protect yourself and avoid hurting others and the environment. Participate in the necessary safety training for the post and cooperate with the drill of emergency plan.

严格执行岗位安全操作规程。及时汇报工作中的任何事故事件和危险源。

Strictly follow EHS procedure. Report any EHS accident and hazard in a timely manner.

执行主管安排的其他工作

Perform the other tasks arranged by supervisors

岗位要求：

2022年统招本科及以上应届毕业生

药学、化学等相关专业

企业介绍

BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that leverages our strong internal oncology biology expertise with unique access to large number of patient-derived tumor biopsies. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer, including a second-generation BRAF inhibitor in Phase I, a best-in-class PARP inhibitor in Phase I ,a best-in-class BTK inhibitor in Phase I. Global phase 2/3 trials are expected starting from 2015.Besides that,2 to 3 small molecule and immune oncology mAb drugs are expected to enter clinical trial each year. For more information, please visit our website at www.beigene.com
百济神州（北京）生物科技有限公司是一家位于北京市中关村生命科学园区的中国生物技术与新药创制公司，致力于研究和开发包括新型化学小分子和生物大分子在内的创新抗癌药物。百济通过自主开发其中国实验室发现的新药，以及同制药公司合作伙伴合作授权共同开发在研新药，以满足中国和亚洲的癌症患者未能满足的医疗需求。百济正在创建一个坚实的生物标志物和生物信息学平台，用于识别癌症患者中有可能受益于相关药物或治疗方法的病人亚群，并通过研究药物的敏感性和靶标分子之间的关系来研制出更有效和更安全的靶向创新药物。更多信息，请访问www.beigene.com.